![](http://acas.orgwp-content/uploads/2021/07/Instagram-1.png)
![](http://acas.orgwp-content/uploads/2021/07/Twitter-1.png)
Twitter feed is not available at the moment.
![](http://acas.orgwp-content/uploads/2021/07/Facebook.png)
New HIV preventive strategy sparks excitement — and protests — at AIDS conference
A new way to prevent HIV infection is generating great buzz -- and more than a bit of controversy -- at this week’s AIDS 2024 Conference in Munich.![]()
The treatment consists of a twice-yearly injection of a drug called lenacapavir.![]()
Early trial results were released in June and generated great excitement, indicating 100% efficacy. On Wednesday, July 24, the full peer-reviewed results were released at the AIDS 2024 conference, confirming the preliminary data.![]()
The trial was sponsored by Gilead Sciences, the California-based maker of the drug.![]()
This treatment offers an alternative to the current standard of core for HIV prevention efforts for over a decade: taking a pill like Truvada every day.![]()
For more info, please go to
New HIV preventive strategy sparks excitement -- and protests -- at AIDS conference
www.npr.org
The final results of a trial for a new HIV preventive strategy are out today. Experts express enthusiasm. But activists at the 2024 AIDS conference in Munich are protesting the likely cost.![](http://acas.orgwp-content/uploads/2021/07/Youtube-1.png)